Last reviewed · How we verify
NCT03798665
A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors
trial testing Pegfilgrastim（PEG-rhG-CSF） in Neutropenia in 800 participants. Status unknown.
6 July 2019
Quick facts
| Lead sponsor | Affiliated Hospital of North Sichuan Medical College |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 800 |
| Start date | 6 July 2018 |
| Primary completion | 6 July 2019 |
| Estimated completion | 6 July 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Pegfilgrastim（PEG-rhG-CSF） — full drug profile →
Conditions studied
- Neutropenia — all drugs for Neutropenia →
Sponsor
Affiliated Hospital of North Sichuan Medical College
Who can join
18 and older, any sex, with Neutropenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective, multicenter, non-interventional registration studies were used in this project . Eight hundreds patients with solid tumors who met the inclusion criteria in six hospitals in Sichuan Province, Sichuan Province, were selected from the first chemotherapy cycle using PEG-rhG-CSF (can be any chemotherapy cycle of the patient), and each subsequent chemotherapy cycle was recorded. The use of PEG-rhG-CSF and related patient outcomes until the end of chemotherapy. Analyze the clinical practice of using PEG-rhG-CSF in the real world.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03798665
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neutropenia
Currently open trials in the same condition.
- NCT07434063 — Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection · recruiting
- NCT07066085 — Serial Blood Count Study · EARLY_PHASE1 · recruiting
- NCT06537726 — Breath Analysis for the Detection of Invasive Fungal Infections · recruiting
- NCT06145321 — Continuous Versus Bolus Administration of G-CSF in Children With Cancer · Phase 4 · active not recruiting
- NCT06422533 — Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients · NA · recruiting
Other Affiliated Hospital of North Sichuan Medical College trials
Trials by the same sponsor.
- NCT03588494 — Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer · Phase 2, PHASE3 · unknown
- NCT03416231 — Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) · Phase 2 · unknown
- NCT04740840 — Anti Inflammatory Treatment of Hypertension · Phase 2, PHASE3 · completed
- NCT04421274 — Bone Marrow Mesenchymal Stem Cells Transfer in Patients With ST-segment Elevation Myocardial Infarction · Phase 2, PHASE3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03798665 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of North Sichuan Medical College
- Last refreshed: 10 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03798665.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing